# Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity

> **NCT07590219** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **University of Sao Paulo General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Severe Obesity
- Cardiovascular Function
- Liraglutide
- Childhood Obesity
- Echocardiography
- Speckle Tracking

## Interventions

- **DRUG:** Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml

## Key facts

- **NCT ID:** NCT07590219
- **Lead sponsor:** University of Sao Paulo General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-30
- **Primary completion:** 2027-04
- **Final completion:** 2028-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07590219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07590219, "Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT07590219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*